ABPI calls for better patient access and new health service funding
What NHS changes does pharma want from a new government?
Pharmaceutical industry leaders have called for the
new government to make wide ranging changes to the NHS and provide significant
new funding following the 8 June General Election.
An industry’s manifesto published by the
Association of the British Pharmaceutical Industry says that spending on
healthcare in the UK is the sixth lowest among the Group of Seven (G7) nations
at 9.9% of GDP, and that this should be increased to the G7 average of 11.3%.
It argues that the UK should be in the top quartile
of OECD countries for patient access to new medicines and vaccines by 2022. UK
patient access is said to be poor in comparison to similar nations.
In the year following launch, patients in France
and Germany are around five times more likely to receive a new medicine than
patients in the UK.
The officials also called for a new pharmaceutical
price regulation scheme, abandonment of the newly introduced £20m budget impact
threshold and implementation of the accelerated access review.
Patient outcomes should be measured through an
independent assessment as part of the NHS innovation scorecard.
The industry also calls for medicines regulation in
the UK to be aligned with the EU, for treaty terms that allow the UK
pharmaceutical industry to freely trade medicines and pharmaceutical supplies
across borders both in the EU and with third countries through free trade
It also calls for the industry to be able to
recruit the best research talent available worldwide.
The Association of British Healthcare Industries has
also published a set of policy recommendations for a new government designed to
increase patient access
What is the likelihood of a new government meeting
at least some of the ABPI’s demands? What election outcome do you think would
be most favourable to patient care and to the industry’s prospects?
ABHI: Manifesto for medtech 2017
ABPI: New Government ‘must be more ambitious in securing a world-class NHS’,
says UK pharmaceutical industry